ARTELO BIOSCIENCES, INC. (ARTL)
ARTELO BIOSCIENCES, INC. (ARTL) is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based therapeutic candidates. The company leverages cannabinoid science to address unmet medical needs across pain management, inflammatory conditions, and neurological disorders.
What the company does
ARTELO Biosciences operates in the emerging cannabinoid therapeutics space, developing proprietary formulations and delivery mechanisms for medical applications. The company’s pipeline focuses on pain syndromes, inflammatory diseases, and neurological conditions where cannabinoid mechanisms may offer therapeutic benefit. Rather than pursuing whole-plant cannabis, the company develops specific cannabinoid compounds and their combinations through traditional drug development pathways.
Its therapeutic approach
The company’s strategy centers on identifying and optimizing cannabinoid combinations that may modulate specific biological pathways implicated in disease. This includes both primary cannabinoid compounds (such as CBD and THC) and their analogs, formulated with precision dosing and delivery systems suitable for clinical use. The company operates under the regulatory frameworks governing pharmaceutical drug development, seeking FDA approval through the standard Investigational New Drug (IND) and clinical trial processes.
Research and development
ARTELO’s pipeline includes candidates in various stages of clinical evaluation, targeting indications such as neuropathic pain, osteoarthritis pain, and certain inflammatory and neurological conditions. The company pursues partnerships and licensing arrangements to advance development while managing capital resources. R&D activities involve formulation chemistry, preclinical pharmacology, and clinical trial management, typical of early-to-mid stage biotech firms.
How to research it
Investors and researchers can examine ARTELO’s regulatory filings through the SEC EDGAR system using CIK 1621221. Key documents include annual 10-K reports (with business description, risk factors, and pipeline status), quarterly 10-Q filings (with financial results and development milestones), and 8-K current reports (material events). Patent filings at the USPTO and clinical trial registrations at clinicaltrials.gov document the company’s intellectual property and trial activity. Publicly available clinical data presentations and regulatory correspondence provide additional insight into the company’s progress and regulatory strategy.